Long-acting beta-agonists and asthma death: how useful are different study designs to evaluate the potential association

Journal of Asthma

Volumn 47, Issue 4, 2010, Pages 434-438

  Weatherall, Mark ^a,b   Wijesinghe, Meme ^b,c   Perrin, Kyle ^b,c   Beasley, Richard ^b,c  

^a UNIVERSITY OF OTAGO WELLINGTON   (New Zealand)

^b CAPITAL AND COAST DISTRICT HEALTH BOARD   (New Zealand)

^c MEDICAL RESEARCH INSTITUTE OF NEW ZEALAND   (New Zealand)

Author keywords

Asthma; Epidemiology; Long acting beta agonists; Mortality; Randomized controlled trial

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FORMOTEROL; LONG ACTING DRUG;

ADVERSE DRUG REACTION; ARTICLE; ASTHMA; CASE CONTROL STUDY; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG FATALITY; EPIDEMIOLOGY; HUMAN; INTERMETHOD COMPARISON; MORTALITY; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SAMPLING ERROR; STATISTICAL ANALYSIS; STUDY DESIGN; UNSPECIFIED SIDE EFFECT;

ADRENERGIC BETA-AGONISTS; ASTHMA; CASE-CONTROL STUDIES; DELAYED-ACTION PREPARATIONS; HUMANS; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 77953349926     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.3109/02770900903556439     Document Type: Article

References (23)

1. Beasley R, Martinez FD, Hackshaw A, Rabe KF, Sterk PJ, Djukanovic R. Safety of long-acting beta agonists: urgent need to clear the air remains. Eur Respir J 2009; 33:3-5.
2. Castle W, Fuller R, Hall J, et al. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment BMJ 1993; 306:1034-1037.
3. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129:15-26.
4. Salpeter SR, Buckley NS, Orniston TM, Salpeter EE. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthmarelated deaths. Ann Intern Med 2006; 144:904-912.
5. Sears MR, Ottosson A, Radner F, Suissa S. Long-acting -agonists: a review of formoterol safety data from asthma clinical trials. Eur Respir J 2009; 33:21-32.
6. Jaeschke R, O'Byrne PM, Mejza F, Nair P, Lésniak W, Brozek J, et al. The safety of long-acting -agonists among patients with asthma using inhaled corticosteroids: systematic review and meta-analysis. Am J Respir Crit Care Med 2008; 178:1009-1016.
7. Bateman E, Nelson H, Bousquet J, Kral K, Sutton L, Ortega H, Yancey S. Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Ann Int Med 2008; 149:33-42.
8. Wijesinghe M, Weatherall M, Perrin K, Harwood M, Beasley R. Risk of mortality associated with formoterol: a systematic review and metaanalysis. Eur Respir J 2009; 34:803-811.
9. Anderson HR, Ayers JG, Sturdy PM, et al., for the Mortality and Severe Morbidity Group of the National Asthma Task Force. Bronchodilator treatment and deaths from asthma: case-control study. BMJ 2005; 330:117-123.
10. Grimes DA, Schulz KF. An overview of clinical research: the lay of the land. Lancet 2002; 359:57-61.
11. Bradburn MJ, Deeks JJ, Berlin JA, Localio AR. Much ado about nothing: a comparison of the performance ofmeta-analytical methods with rare events. Statist Med 2007; 26:53-77.
12. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2008. Available at: http://www.ginasthma.org/ Guidelineitem.asp?l1=2&l21&intId1561. Accessed July 2009.
13. Shrier I, Platt RW, Steele RJ. Mega-trials vs. meta-analysis: precision vs. heterogeneity? Contemp Clin Trials 2007; 28:324-328.
14. Crane J, Pearce N, Flatt A, Burgess C, Jackson R, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-1983: a case control study. Lancet 1989; 1:917-922.
15. Pearce N, Grainger J, Atkinson M, Crane J, Burgess C, et al. Case-control study of prescribed fenoterol and death from asthma in New Zealand 1977-1981. Thorax 1990; 45:170-175. (Pubitemid 20108717)
16. Crane J, Burgess C, Pearce N, Beasley R. The ?-agonist controversy: a perspective. Eur Respir Rev 1993; 3:475-482.
17. Pearce N, Beasley R, Crane J, Burgess C. Pharmacoepidemiology of asthma deaths. In: Hartzema AG, Porta MS, Tilson HH, eds. Pharmacoepidemiology: An Introduction. 3rd ed. Cincinnati, OH: Harvey Whitney, 1993:473-494.
18. Beasley R, Burgess C, Pearce N, Woodman K, Crane J. Confounding by severity does not explain the association between fenoterol and asthma death. Clin Exp Allergy 1994; 24:660-668.
19. Rea HH, Scragg R, Jackson R, Beaglehole R, Fenwick J, Sutherland DC. A case-control study of deaths from asthma. Thorax 1986; 41:833-839.
20. Pearce N, Crane J. Epidemiological methods for studying the role of beta agonist therapy in asthma mortality. In: Beasley R, Pearce NE, eds. The Role of Beta Agonist Therapy in AsthmaMortality. New York: CRC Press, 1993:67-83.
21. DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Stat 1999; 53:177-190.
22. Drazen JM, O'Byrne PM. Risks of long-acting beta-agonists in achieving asthma control. N Engl J Med 2009; 360:1671-1672.
23. Hedges LV, Pigott TD. The power of statistical tests in meta-analysis. Psychol Methods 2001; 6:203-217